切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2012, Vol. 06 ›› Issue (04) : 358 -364. doi: 10.3877/cma. j. issn.1674-0807.2012.04.002

论著

用ROC 曲线评价雌激素、卵泡刺激素、黄体生成素判断乳腺癌患者绝经状态
孟祥颖1, 单彬2, 宋三泰1, 孙冰1, 吴世凯1,(), 江泽飞1, 王涛1, 张少华1   
  1. 1.100071 北京,军事医学科学院附属医院乳腺肿瘤内科
    2.100850 北京,军事医学科学院卫生勤务与医学情报研究所
  • 收稿日期:2012-03-05 出版日期:2012-08-01
  • 通信作者: 吴世凯
  • 基金资助:
    中国抗癌协会乳腺癌专业委员会项目(CBCSG008)

Evaluation of the role of estradiol, follicle stimulating hormone and luteinizing hormone in discriminating menopausal status of invasive breast cancer patients by receiver operating characteristics curve

Xiang-ying MENG1, Bin SHAN1, San-tai SONG1, Bing SUN1, Shi-kai WU,1(), Ze-fei JIANG1, Tao WANG1, Shao-hua ZHANG1   

  1. 1.Breast Cancer Department of Affiliated Hospital, Academy of Military Medical Sciences, 100071 Beijing,China
  • Received:2012-03-05 Published:2012-08-01
  • Corresponding author: Shi-kai WU
引用本文:

孟祥颖, 单彬, 宋三泰, 孙冰, 吴世凯, 江泽飞, 王涛, 张少华. 用ROC 曲线评价雌激素、卵泡刺激素、黄体生成素判断乳腺癌患者绝经状态[J/OL]. 中华乳腺病杂志(电子版), 2012, 06(04): 358-364.

Xiang-ying MENG, Bin SHAN, San-tai SONG, Bing SUN, Shi-kai WU, Ze-fei JIANG, Tao WANG, Shao-hua ZHANG. Evaluation of the role of estradiol, follicle stimulating hormone and luteinizing hormone in discriminating menopausal status of invasive breast cancer patients by receiver operating characteristics curve[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2012, 06(04): 358-364.

目的

应用ROC 曲线评价雌二醇(estradiol,E2)、卵泡刺激素(follicle stimulating hormone,FSH)和黄体生成素(luteinizing hormone,LH)3 项性激素对浸润性乳腺癌患者绝经状态的判断能力。

方法

分析本院128 例绝经前及204 例已绝经浸润性乳腺癌患者的性激素检测结果。 应用ROC 曲线评价单项性激素及它们联合的判断能力和判断点(Cut-off Point)。

结果

单项E2、FSH 和LH 的ROC 曲线下面积分别为0.939 5 (95%CI:0.911 0 ~0.967 9)、0.971 4 (95%CI:0.951 4 ~0.991 4)和0.905 3(95%CI:0.868 1 ~0.942 4);Youden 指数最大时的判断点分别为49.52 pg/ml、21.96 mU/ml 和13.25 mU/ml。 FSH 的ROC 曲线下面积分别和E2(P=0.036)、LH 相比(P<0.001),差别均具有统计学意义。 经计算E2 和FSH 进入联合判断模型,联合判断的曲线下面积为0.977 4 (95%CI:0.959 7 ~0.995 2),Youden 指数最大时的判断点的绝经概率(P绝经)= 0.46。

结论

单项E2、FSH 和LH 均可判断乳腺癌患者的绝经状态,其中FSH 的能力好于E2 和LH。 而E2 和FSH 的联合判断好于单项指标。 由于LH的ROC 曲线下面积最小,经计算没能进入联合判断模型,故不推荐用其判断乳腺癌患者的绝经状态。 可根据临床需要,调整ROC 曲线的绝经概率,选择判断点,并了解在该判断点下的误诊率或漏诊率的大小。

Objective

To evaluate the roles of estradiol (E2), follicle stimulating hormone (FSH) and luteinizing hormone (LH) in discriminating menopausal status of invasive breast cancer patients using receiver operating characteristics (ROC) curve.

Methods

Analysis was undertaken among 128 premenopausal and 204 postmenopausal invasive breast cancer patients. The efficient and useful cut-off points of the three sex hormones were achieved based on ROC curve.

Results

The areas under the ROC curve of E2, FSH and LH were 0.939 5 (95%CI:0.911 0-0.967 9),0.9714 (95%CI: 0.951 4-0.991 4) and 0.905 3 (95%CI:0.868 1-0.942 4) respectively, and the cut-off point was 49.52 pg/ml, 21.96 mU/ml and 13.25 mU/ml respectively, with a maximum of the Youden index. The area under the ROC curve of FSH was significantly better than E2 (P=0.036) and LH (P<0.001). E2 and FSH were selected into the logistic regression model,the area under the ROC curve was 0.977 4 (95%CI:0.959 7-0.995 2). The probability of menopause (Pm) was 0.46 with a maximum of the Youden index.

Conclusions

E2, FSH and LH can effectively discriminate menopausal status of invasive breast cancer patients. The discrimination capabicity of FSH is significantly better than that of E2 or LH. The discrimination capability of combining E2 and FSH is better than using any of the three hormones independently. LH is not recommended to identify menopausal status, because it fails to be selected into the logistic regression model, and the area under the ROC curve is the least among the three hormones. The cut-off point may be adjusted according to the demand of clinical practice.

表1 3 种性激素的ROC 曲线下面积及其曲线下面积比较
图1 雌激素(E2)、卵泡刺激素(FSH)、黄体生成素(LH)分别判断绝经的ROC 曲线图
表2 雌激素(E2)、卵泡刺激素(FSH)、黄体生成素(LH)Youden 指数最大时的判断点及敏感度和特异度
图2 雌激素和卵泡刺激素联合判断绝经的ROC 曲线
图3 应用Excel 软件编写的卵泡刺激素(FSH)和雌激素(E2)联合判断绝经图
表3 雌激素和卵泡刺激素联判断绝经时不同敏感度和特异度对应的绝经概率(P绝经)
[1]
NCCN Clinical Practice Guidelines in OncologyTM Breast Cancer, (Version 2) 2008 [OL]. [2008-01-09]. http:/ /www.nccn.org (Accessed 1/9/08).
[2]
Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group [J]. J Clin Oncol,2000,18(22):3758-3767.
[3]
Mouridsen H, Gershanovic M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase Ⅲstudy of the International Letrozole Breast Cancer Group [J]. J Clin Oncol,2001,19(10):2596-2606.
[4]
Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer[J]. Ann Oncol, 2003,14(9):1391-1398.
[5]
孙冰,孟祥颖,宋三泰,等.乳腺癌患者血清雌二醇、卵泡刺激素及黄体生成素检测结果分析:西门子吖啶酯化学发光法检测报告[J/CD].中华乳腺病杂志:电子版,2012,6(3):244-252.
[6]
Lutchman Singh K,Muttukrishna S,Stein RC,et al. Predictors of ovarian reserve in young women with breast cancer [J].Br J Cancer,2007,96(12):1808-1816.
[7]
Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer [J]. Fertil Steril,2010,94(2):638-644.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要